Another novel approach for improving antitumor immunity involves the in situ reprogramming of tumor cells into “artificial” antigen-presenting cells (APCs) that express OX40L using nanoparticles that are loaded with an OX40L plasmid. The gene discussed is TNFSF4; the disease is neoplasm.